Comment on "Clinical experience with SGLT2 inhibitors in patients with systemic lupus erythematosus".

No abstract is available for this paper.

• Publication year

  2025

• Venue

  International Urology and Nephrology

• Publication date

  2025-11-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11255-025-04909-0PMID 41222810
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis

  2025cited by this paper
• Clinical experience with sodium-glucose transport 2 (SGLT2) inhibitors in patients with systemic lupus erythematosus.

  2025cited by this paper
• SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy

  2023cited by this paper
• Lupus nephropathy beyond immunosuppression: Searching for nephro and cardioprotection

  2023cited by this paper
• EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

  2023cited by this paper
• The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy

  2022cited by this paper
• Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment

  2013cited by this paper
• Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment

  2013cited by this paper
• Statistics notes: Absence of evidence is not evidence of absence

  1995cited by this paper
• Absence of evidence is not evidence of absence.

  1995cited by this paper

• No citing papers are available for this paper.